D
Inhibikase Therapeutics, Inc. IKT
$1.44 $0.032.13% NASDAQ
Recommendation
Prev Close
$1.41
Volume
160,424
Avg Vol (90D)
165,903
Market Cap
$106.00M
Dividend & Yield
--
52-Week Range
$1.33 - $4.20
P/E (TTM)
--
EPS (TTM)
-$0.56
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
11/25/2025 - TipRanks Financial Blog
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
11/21/2025 - TipRanks Financial Blog
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offering
11/21/2025 - GuruFocus
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share
11/21/2025 - SeekingAlpha.com: All News
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share
11/21/2025 - Seeking Alpha - Healthcare
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and ...
11/21/2025 - GuruFocus
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
11/21/2025 - The Fly
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and ...
11/21/2025 - GuruFocus
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
11/21/2025 - Globe Newswire
Inhibikase Therapeutics (IKT) Launches Public Offering of Common Stock
11/20/2025 - GuruFocus
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
11/20/2025 - GuruFocus
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
11/20/2025 - GuruFocus
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
11/20/2025 - The Fly
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants
11/20/2025 - Seeking Alpha - Healthcare
Inhibikase Therapeutics (IKT) Plans Global Phase 3 Trial for PAH Treatment
11/20/2025 - GuruFocus
Inhibikase Therapeutics (IKT) Launches Public Stock Offering
11/20/2025 - GuruFocus
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
11/20/2025 - Globe Newswire
Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
11/20/2025 - The Fly
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
11/20/2025 - Globe Newswire
Inhibikase Therapeutics (NASDAQ:IKT) Issues Quarterly Earnings Results
11/16/2025 - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Shares Down 4.4% - Here's What Happened
11/16/2025 - MarketBeat
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent ...
11/14/2025 - GuruFocus
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
11/14/2025 - Globe Newswire
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) and Prime Medicine (NASDAQ:PRME)
11/9/2025 - Ticker Report
Inhibikase Therapeutics (NASDAQ:IKT) Given Sell (D-) Rating at Weiss Ratings
10/26/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$52.72M
EBIT (TTM)
-$52.79M
Net Income (TTM)
-$47.66M
Balance Sheet
Total Assets (Q)
$79.59M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$6.70M
Book Value Per Share (Q)
$0.9745
Cash Flow
Cash from Operations (TTM)
-$25.62M
Cash from Investing (TTM)
-$36.61M
Cash from Financing (TTM)
$99.58M
Net Change in Cash (TTM)
$37.36M
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
2.09
7-Day Total Return
-3.36%
30-Day Total Return
-8.86%
60-Day Total Return
-13.77%
90-Day Total Return
-18.64%
Year to Date Total Return
-56.23%
1-Year Total Return
-48.57%
2-Year Total Return
49.22%
3-Year Total Return
-57.04%
5-Year Total Return
--
52-week Low
Nov 03, 2025 - $1.33
52-week High
Dec 18, 2024 - $4.20
Valuation
Market Cap
$106.00M - Micro Cap
Enterprise Value
$28.67M
Price/Sales (TTM)
--
Price/Book (Q)
1.45
Dividends and Shares
Shares Outstanding
90.05
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.inhibikase.com
Phone Number
678 392 3419
Address
3350 Riverwood Parkway SE
Atlanta, GA 30339
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed